Elimination of iomeprol by hemodialysis.
Iomeprol is commercially a relatively new type of contrast medium. There have been no reports concerning its dialysability and safety when administered to patients with end-stage renal failure undergoing regular therapeutic hemodialysis (HD). One hundred milliliters of iomeprol (350 mgl/ml) was injected intravenously at computed tomography in 10 patients suffering from chronic renal failure. HD was then performed within 30 min after the start of iomeprol injection. The duration of HD was 4 h and blood samples were taken at 15, 30 min, 1, 2 and 4 h after its start. Mean dialysance of urea was 176.0-182.9 ml/min, compared to 131.4-133.3 ml/min for iomeprol. Elimination rate of iomeprol was 821.4 +/- 4.6% 4 h after the start of HD. Two of the 10 patients had side effects. One of them complained of a heat sensation and the other of sneezing and rash. As 4-h HD effectively removed iomeprol from the body and there were no severe side effects, it is concluded that iomeprol is suitable for HD patients.
Ueda
J
J
Department of Radiology, Sumitomo Hospital, Osaka, Japan.
Furukawa
T
T
Higashino
K
K
Takahashi
S
S
Araki
Y
Y
Sakaguchi
K
K
D000368:Aged; D003287:Contrast Media / Q000009:adverse effects / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007479:Iopamidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D013997:Time Factors
D003287:Contrast Media; C057937:iomeprol; D007479:Iopamidol